OPKO Health Files 8-K for Financial Results

TL;DR

**OPKO Health just filed an 8-K announcing its financial results, so expect market movement once the numbers are out.**

AI Summary

OPKO Health, Inc. filed an 8-K on February 27, 2024, to report its "Results of Operations and Financial Condition" and include "Financial Statements and Exhibits." This filing, under SEC File Number 001-33528, indicates the company is providing an update on its financial performance. The company's principal executive offices are located at 4400 Biscayne Blvd., Miami, Florida 33137.

Why It Matters

This 8-K signals that OPKO Health, Inc. has released its latest financial performance data, which is crucial for investors to assess the company's health and future prospects. The market will react to the specifics of these results, impacting stock price and investor confidence.

Risk Assessment

Risk Level: medium — The 8-K announces the filing of financial results, which can significantly impact the company's stock price depending on whether the results meet, exceed, or miss expectations.

Key Numbers

• N/A — Financial Results (Specific financial results are not provided in this excerpt of the 8-K filing.)

Key Players & Entities

• OPKO HEALTH, INC. (company) — Registrant
• February 27, 2024 (date) — Date of earliest event reported/Filing date
• Delaware (location) — State of Incorporation
• Miami, Florida (location) — Business Address City/State
• 001-33528 (identifier) — SEC File Number

FAQ

Key Financial Figures

• $0.01 — ch registered Common Stock , par value $0.01 per share OPK NASDAQ Global Select M

Filing Documents

• opk20240226_8k.htm (8-K) — 28KB
• ex_630674.htm (EX-99.1) — 104KB
• ex_630674img001.jpg (GRAPHIC) — 4KB
• 0001437749-24-005707.txt ( ) — 278KB
• opk-20240227.xsd (EX-101.SCH) — 3KB
• opk-20240227_def.xml (EX-101.DEF) — 11KB
• opk-20240227_lab.xml (EX-101.LAB) — 15KB
• opk-20240227_pre.xml (EX-101.PRE) — 11KB
• opk20240226_8k_htm.xml (XML) — 3KB

02

ITEM 2.02. Results of Operations and Financial Condition. On February 27, 2024, OPKO Health, Inc. (the "Company") issued a press release announcing operating and financial highlights for the quarter ended December 31, 2023. The press release also contains information on how to access the conference call the Company is hosting to provide a business update and discuss its financial and operating results for the fourth quarter ended December 31, 2023, as well as provide financial guidance. A copy of the press release is attached hereto as Exhibit 99.1. The information included herein and in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 as amended or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of the Company dated February 27, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OPKO Health, Inc. By: /s/ Adam Logal Date: February 27, 2024 Name: Adam Logal Title: Senior Vice President, Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR